Cargando…
Steered Molecular Dynamics Simulations Reveal the Likelier Dissociation Pathway of Imatinib from Its Targeting Kinases c-Kit and Abl
Development of small molecular kinase inhibitors has recently been the central focus in drug discovery. And type II kinase inhibitors that target inactive conformation of kinases have attracted particular attention since their potency and selectivity are thought to be easier to achieve compared with...
Autores principales: | Yang, Li-Jun, Zou, Jun, Xie, Huan-Zhang, Li, Lin-Li, Wei, Yu-Quan, Yang, Sheng-Yong |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795779/ https://www.ncbi.nlm.nih.gov/pubmed/20041122 http://dx.doi.org/10.1371/journal.pone.0008470 |
Ejemplares similares
-
Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib
por: Zhu, Guangrong, et al.
Publicado: (2020) -
Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate
por: Rausch, Jessica L., et al.
Publicado: (2016) -
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
por: Mesa, Ruben A
Publicado: (2007) -
Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
por: Okabe, Seiichi, et al.
Publicado: (2014) -
Cytotoxicity and phytochemical profiles of Phyllanthus emblica stem barks with in silico drug-likeliness: Focusing on antidiabetic potentials
por: Quranayati, Quranayati, et al.
Publicado: (2022)